Completed- Automated flow control in a disruptive antibody analytical platform: FIDA
To develop new vaccines, an efficient tool characterizing antibody binding is needed. The platform FIDA, integrating complex fluid handling, will take up this challenge.
This project is completed now. If interested, feel free to contact us.
Antibodies are a significant component of modern medicine, whether for treating diseases or the R&D of new vaccines.
However, antibody testing is currently done with artificial assays based on non-native sample materials, failing to accurately predict the actual biological events in human patients.
In addition, the present methods to evaluate antibodies are tedious and time-consuming and can lead to false results due to the sample dilution required and the low analytical sensitivity.
All these drawbacks lead to considerable costs to develop new therapeutic antibodies or vaccines, limiting the R&D in this field and the possibility for small companies to build a new product.
In this context, finding a better way to characterize antibodies and antibody binding is urgent: this is the purpose of FIDA.
FIDA is a patented platform that allows one to perform immunological measurements under native conditions in less than 20 min and with up to 10 times higher sensitivity than current tools.
This project aims to bring the FIDA prototype to the market with the support of pharmaceutical companies and Denmark’s leading public health and infectious diseases vigilance body.
Antibody analytical platform: our role
We will bring our expertise in flow control to FIDA to achieve complex and precise fluid handling in the analysis platform.
Thanks to an upgraded version of the OEM flow controller, uniform pressure will be applied to 8 capillaries simultaneously, allowing parallelized detection.
FIDA software will be coupled with Elveflow ESI software to control sample injection and analysis. Great care will be taken to develop a product compatible with large-scale production.
Finally, the new platform will be tested to assess performance in antibody characterization and identify any potential deficiencies, particularly regarding flow control.
This project has received funding from the European Union’s Horizon 2020 EIC-FTI under grant agreement No 878727 (FIDA).
